Evidence map›Paper›PMID 41325134›Full record

ReviewClinical and experimental immunology2025

Clinical and experimental treatment of advanced melanoma with a focus on immunotherapy.

Lucy Millar, Rafael Di Marco Barros, Matthaios Kapiris, Christos Nikolaou, Marco Gerlinger, Yin Wu

Abstract readReview
In one paragraph

Review in Clinical and experimental immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lucy MillarCentre for Inflammation Biology and Cancer Immunology, King's College London, London, UK.
Rafael Di Marco BarrosCentre for Inflammation Biology and Cancer Immunology, King's College London, London, UK.
Matthaios KapirisCentre for Inflammation Biology and Cancer Immunology, King's College London, London, UK.
Christos Nikolaou4th Oncology Clinic, Henry Dunant Hospital, Athens, Greece.
Marco GerlingerBarts Cancer Institute, Queen Mary University of London, London, UK.
Yin WuCentre for Inflammation Biology and Cancer Immunology, King's College London, London, UK.ORCID 0000-0003-4080-3935

Funding

Cancer Research UKCRUK City of London Centre Clinical Academic Training Programme - Cohort 2024 SEBCATP-2024/100003Wellcome TrustWellcome Trust 220589/Z/20/Z
6 · The paper itself

Abstract

Melanoma is currently the fifth most common cancer in the UK, and its incidence is rising. Although surgery is curative for many early-stage tumours, advanced disease which is inoperable has historically also been considered incurable. Recent and rapid advances in cancer immunotherapy, particularly immune checkpoint inhibitors, have now revolutionized the management of advanced melanoma with many patients likely being cured. Here, we review the immunobiology of melanoma, the growing list of standard-of-care immunotherapies and the considerations around which treatment regimen to use. We also review evidence from recent clinical trials of promising novel immunotherapies which will hopefully help patients who do not benefit from current treatments.

Indexed as

Immune Checkpoint InhibitorsImmunotherapyMelanomaSkin NeoplasmsAnimalsClinical Trials as TopicHumansImmune Checkpoint InhibitorsCancer ImmunologyImmune Checkpoint InhibitorsImmunotherapyMelanoma

Identifiers

PMID41325134
PMCPMC12732990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.